Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Treating non-osteoporotic compression fractures in patients with multiple myeloma, a blood cancer, shows that the use of vertebroplasty-a minimally invasive treatment performed by interventional radiologists using imaging guidance that stabilizes collapsed vertebrae with the injection of medical-grade bone cement into the spine-results in a reduction of pain, medication usage and disability, according to researchers in the largest study of its kind at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

Mayo Clinic to form new permanent professorship for cancer research

Mayo Clinic is forming a new permanent professorship to augment cancer research that will focus on finding new treatments and preventive measures to reduce the incidence of cancer.

11 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

Study validates Chronix Biomedical’s serum DNA blood tests for early, accurate detection of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests for the early and accurate detection of breast cancer. The Chronix tests detect the circulating DNA that is released into the blood stream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseases—changes that can be used to identify disease processes at an early stage and to track responses to treatment.

9 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

Senesco insiders elect to convert common stock formerly held by Stanford Venture Capital at $0.83

Senesco Technologies, Inc. reported today that the insiders of the Company who had previously purchased all of the convertible debentures, warrants and common stock of Senesco which were formerly held by Stanford Venture Capital Holdings, Inc. have elected, subject to shareholder approval, to convert the convertible debentures at a conversion price of $0.83.

6 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

The Government of Quebec's Ministère de la santé et des services sociaux has approved the addition of Revlimid(R) (lenalidomide) to the Province's Drug Formulary as a third-line therapy for multiple myeloma patients. The cost of the drug will be reimbursed under the Province's medicare system.

25 Feb 2010

Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria

Today, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Science, VOL 327, ISSUE 5968). This proprietary new class of antibiotics is effective against multi-drug resistant Gram-negative bacteria, opening up new treatment options for serious and often life-threatening infections. The most advanced drug candidate in this new class, POL7080, selectively kills the dangerous bacteria Pseudomonas aeruginosa.

19 Feb 2010

Charity Navigator bestows MMRF coveted 4-star rating for efforts in finding cure for multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) announced today that it has received a 4-star rating from Charity Navigator, America's largest independent evaluator of charitable donations, for demonstrating exceptional fiscal responsibility in its efforts to bring patients the next generation of treatments and find a cure for multiple myeloma. This is the seventh consecutive year the MMRF has been honored with this distinguished recognition.

18 Feb 2010

Senesco Technologies announces financial results for quarter ended December 31, 2009

Senesco Technologies, Inc. today reported financial results for the three months ended December 31, 2009.

17 Feb 2010

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

16 Feb 2010

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.

14 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

9 Feb 2010

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Key cellular defect in protein synthesis can lead to cancer susceptibility

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

Mayo Clinic to form new permanent professorship for cancer research

Abbott announces definitive agreement to acquire Facet Biotech

Study validates Chronix Biomedical’s serum DNA blood tests for early, accurate detection of breast cancer

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

Senesco insiders elect to convert common stock formerly held by Stanford Venture Capital at $0.83

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria

Charity Navigator bestows MMRF coveted 4-star rating for efforts in finding cure for multiple myeloma

Senesco Technologies announces financial results for quarter ended December 31, 2009

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in